Navigation Links
Kuvan Receives Priority Review Status From Health Canada
Date:6/10/2009

NOVATO, Calif., June 10 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has received notice of priority review status for Kuvan(R) (sapropterin dihydrochloride) as an oral treatment for patients with phenylketonuria (PKU) from Health Canada. Priority review provides for a shortened submission review of 180 days versus the standard twelve months. BioMarin plans to file a marketing application for Kuvan in Canada in the third quarter of 2009, and with priority review status, a decision for marketing approval is expected in the first half of 2010.

"Priority review status from Health Canada marks another milestone in our efforts to commercialize Kuvan worldwide as it is granted for serious, life-threatening or severely debilitating diseases for which no approved medical therapy exists in Canada," said Steve Aselage, Senior Vice President and Chief Business Officer of BioMarin. "Along with our partners Merck Serono and Asubio, we remain dedicated to serving the PKU community and providing a therapeutic option in the management of this disease."

About Kuvan

Kuvan(R) (sapropterin dihydrochloride) Tablets are indicated in the United States to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet.

The active ingredient in Kuvan, sapropterin dihydrochloride, is the synthetic form of 6R-BH4 (tetrahydrobiopterin), a naturally occurring enzyme cofactor that works in conjunction with phenylalanine hydroxylase (PAH) to metabolize Phe.

Kuvan has received orphan drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA). Kuvan ha
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan
2. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
3. Kuvan Receives Positive Opinion From CHMP for European Approval
4. Kuvan Receives Marketing Approval in the European Union
5. BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
6. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
7. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
10. IsoTis Receives FDA Clearance for Accell Family of Products
11. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... May 27, 2015 RXi Pharmaceuticals Corporation ... on discovering and developing innovative therapies primarily in ... it has commenced a public offering of shares ... of its common stock and overallotment purchase rights ... shares of common stock, warrants and overallotment purchase ...
(Date:5/27/2015)... , May 26, 2015 Research and ... the "Global Breast Cancer Monoclonal Antibodies Market ... Globally, Roche seems to dominate the breast ... Its block buster molecule, Herceptin has been able ... was found that breast cancer cells become recalcitrant ...
(Date:5/27/2015)... 27, 2015 Expanding in a big ... Avalon Biomed Inc. recently inked a deal ... Dental Co. Ltd. , the largest endodontic distributor in ... international market for Avalon Biomed, which manufactures Grey MTA ... silicate-based dental cements that have won renown from dentists ...
(Date:5/27/2015)... , May 27, 2015  Tikcro Technologies Ltd. (OTCQB: ... March 31, 2015. Aviv Boim ... continued pre-clinical work to generate functional specific antibodies, targeting ... stage, we are encouraged by the development progress. We ... new antibodies which modulate immune checkpoints gain clinical acceptance ...
Breaking Biology Technology:RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 3Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 2Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 3Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3
... never heard of "graphene" before, you might know something about ... announcements. Two physicists at the University of Manchester (UK) ... regarding the two-dimensional material graphene," carbon flakes that are only ... steel and as conductive as copper. But, what happens ...
... for medicine awarded to Robert Edwards, the pioneer British biologist ... doubts about the importance of ,test tube babies, that have ... put to rest," says Michael S. Opsahl, M.D., ... Magazine. "IVF, once perceived as expensive and a ...
... Enerkem Named A Top Global Cleantech Company ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) ...
Cached Biology Technology:Beyond the Nobel Prize, what's next for graphene? 2Nobel Spotlight on IVF Boosts Family Building Procedures 2Enerkem Named A Top Global Cleantech Company 2Enerkem Named A Top Global Cleantech Company 3Enerkem Named A Top Global Cleantech Company 4Enerkem Named A Top Global Cleantech Company 5Enerkem Named A Top Global Cleantech Company 6Enerkem Named A Top Global Cleantech Company 7
(Date:5/11/2015)... Calif. , May 11, 2015  Synaptics ... of human interface solutions, today announced the appointment ... President and Chief Financial Officer, reporting to ... replaces Synaptics, current Chief Financial Officer, Kathleen ... 2014. Mr. Ali brings extensive ...
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
(Date:5/8/2015)... -- Synaptics Inc. (NASDAQ: SYNA ), the leading developer ... executive management team will present at the following investor events: ... Conference Date: May 18, 2015 Time: 10:40am ET ... Cowen and Company Technology, Media & Telecom ... New York Palace Hotel, New York, NY ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2
... the globe came together at Rensselaer Polytechnic Institute Nov. ... Energy Research to discuss the development of technologies that ... on Earth: photosynthesis. The conference, titled "At the Interface ... Lakshmi, assistant professor of chemistry and chemical biology and ...
... and depth of the Deepwater Horizon oil spill ... severity of ecological damage and to develop restoration plans for ... report by the National Research Council. A broad approach ... production -- in addition to replacing natural resources damaged by ...
... each to put towards developing technologies such as instrumentation, ... genomics research. "We received over 40 ... imaginative research ideas," commented Dr. Mark Poznansky, President and ... Ontario,s researchers and their work that might not be ...
Cached Biology News:Solar Energy Research Conference at Rensselaer draws solar experts from around the world 2Solar Energy Research Conference at Rensselaer draws solar experts from around the world 3New report offers broad approach to assessing impacts of ecological damage 2New report offers broad approach to assessing impacts of ecological damage 3200 thousand dollars awarded to genomics researchers to spark new research technology development 2200 thousand dollars awarded to genomics researchers to spark new research technology development 3
For testing the AQUA technique on your MS instruments....
0.2ml Gradient Block MBSR. Robot compatible block ejection mechanism. Stackable. (96 well block - holds 1 plate 0.2ml x 96 well plate)...
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
A Highly Purified, Cost-Effective Taq DNA Polymerase...
Biology Products: